<DOC>
	<DOCNO>NCT02918591</DOCNO>
	<brief_summary>It show patient type 2 diabetes ( T2D ) high risk cardiovascular disease ( CVD ) receive Empagliflozine compare placebo low rate death cardiovascular cause , non-fatal MI , non-fatal stroke well death cause hospitalization heart failure . This low incidence cardiovascular disease individual treat selective inhibitor renal sodium-glucose co-transporters ( SGLTs ) associate reduction blood level fibroblast growth factor 23 ( FGF23 ) increase blood level Klotho . Therefore investigate blood level fibroblast growth factor 23 ( FGF23 ) Klotho type 2 diabetic patient treat Empagliflozine The investigator anticipate patient treated Empagliflozine decrease level FGF23 increase level Klotho would provide good explanation beneficial cardiovascular effect selective inhibitor renal sodium-glucose co-transporters ( SGLTs )</brief_summary>
	<brief_title>Cardiovascular Effects Empagliflozine</brief_title>
	<detailed_description>Recently show patient type 2 diabetes high risk cardiovascular disease ( CVD ) receive Empagliflozine compare placebo low rate death cardiovascular cause , non-fatal MI , non-fatal stroke well death cause hospitalization heart failure Empagliflozine selective inhibitor renal sodium-glucose co-transporters ( SGLTs ) approve treatment type 2 diabetes . It associate weight loss , reduction blood pressure without increase heart rate , improve marker arterial stiffness vascular resistance , visceral adiposity , albuminuria urate . Renal sodium-glucose cotransporter ( SGLT2 ) reside proximal tubule ( PT ) .The latter anatomically expose initial glomerular filtrate . Therefore proximal tubule ( PT ) cell play variety role amongst receptor mediate protein endocytosis , reabsorption sodium , glucose phosphate At steady state approximately 85 % filtered phosphate Pi load reabsorb kidney sodium phosphate transporter find apical membrane proximal tubule cell . These transporter also affect fibroblast growth factor 23 ( FGF23 ) . Fibroblast growth factor 23 ( FGF23 ) hormone mainly secrete osteocyte osteoblast bone , level FGF23 increase significantly early stage chronic kidney disease ( CKD ) may play critical role mineral ion disorder bone metabolism patient . Recent publication also show FGF23 cofactor , Klotho , may play independent role directly regulate bone mineralization instead produce systematic effect . It augment phosphaturia affect sodium phosphate co transporter : mainly : NaP2a Fibroblast growth factor 23 ( FGF23 ) FGF23 bind receptor complex consist FGFR1 , 3 4 Î± Klotho activate ERK1/2 lead internalization degradation NaP2a . Klotho transmembrane protein identify age suppressor protein , express mainly distal tubule lesser extent PTC serve co-receptor along FGF receptor bind FGF23 DCT It find mainly kidney distal tubular epithelium , parathyroid gland , epithelial cell choroid plexus brain human vascular tissue .Recently demonstrate PCT well . Higher FGF23 level find associate cause mortality patient end stage renal disease , dialysis , CKD stag 2-4 general population FGF23 numerous adverse effect might contribute CVD : It associate abnormal leave ventricular geometry , include high leave ventricular mass , high leave ventricular mass volume ratio , great risk remodel atrial fibrillation . It also activate renin angiotensin system promote sodium reabsorption distal tubule kidney contribute volume overload hypertension Reduction Klotho 's level observe normal age renal disease , diabetes mellitus hypertension . Klotho also exist secrete soluble form distinct action . The secreted form increase nitric oxide ( NO ) availability , protect endothelial dysfunction . It possess ant oxidative action demonstrate spontaneous hypertensive rat . Chronic kidney disease mouse overexpressing Klotho demonstrate almost aortic calcification . The complex Klotho/ FGF23 induces urinary phosphate excretion , reduces serum level 1,25 ( OH ) Vit D inhibit secretion PTH . Enhanced phosphaturia ameliorate vascular calcification . Indeed vessel produce Klotho endogenous inhibitor calcification . Recently Dapagliflozine renal sodium-glucose cotransporter SGLT2 inhibitor demonstrate enhanced ERK phosphorylation cell culture colon cancer If phosphorylation occur ERK renal proximal tubule cell phosphorylation would increase internalization degradation NaP2a lead turn hypophosphatemia decrease FGF23 level increase Klotho Therefore investigator search blood level fibroblast growth factor 23 ( FGF23 ) Klotho type 2 diabetic patient treat Empagliflozine</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 Diabetes HbA1C:7.510 . Age &gt; 18 years80 year Cardiovascular risk factor : Ischemic heart disease ( IHD ) Status Post Myocardial Infarct ( SPMI ) , Angina Pectoris ( AP ) , stable , unstable AP , Peripheral vascular disease ( PVD ) , Cerebro vascular accident ( CVA ) , &gt; 6 month Chronic renal failure ( CRF ) , eGFR &gt; 50 ml/min Patients require stable glucoselowering therapy least 12 week enter study . Age &lt; 18 year Pregnanacy , breastfeed . eGFR &lt; 45mg/dl Type1 Diabetes Active urogenital infection , infection last 6 month . Recurrent UTI genital infection . SGLT2 treatment . History ketoacidosis . Pulmonary embolism/DVT last year . Malignancy active , ( last 10 year ) . Steroid use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>